Substance Misuse To Psychosis for Stimulants

Schizophrenia and Related Disorders Clinical Trial

Official title:

Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03485417
• Other study ID #: SToP-S
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: June 1, 2019
• Est. completion date: May 31, 2025

Study information

• Verified date: July 2023
• Source: The University of Hong Kong
• Contact: albert KK Chung, Dr
• Phone: +85222553060
• Email: chungkka[@]hku.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection. Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes. With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 50 Years

Eligibility

Inclusion Criteria:

• Stimulant use disorder with psychosis or positive stimulant urine test results twice in a month with psychosis

Exclusion Criteria:

• Age <16 years old
• Unable to read English or Chinese
• Unable to give informed consent
• Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
• Had been diagnosed to have Schizophrenia
• Had been diagnosed to have other substance-induced psychotic or mood disorder, including alcohol
• Had been diagnosed to have bipolar disorder viii. Had been diagnosed to have major depressive disorder with psychotic features
• Had been taking any maintenance dose of oral antipsychotics continuously =12 weeks AND with psychotic symptoms in remission
• Had been receiving any maintenance dose of long-acting injectable (LAI/depot) antipsychotics continuously =4 month AND with psychotic symptoms in remission
• Had known hypersensitivity to risperidone (oral or LAI), paliperidone (oral or LAI), or aripiprazole (oral or LAI)
• Had known history of tardive dyskinesia
• Had known history of neuroleptic malignant syndrome
• Pregnant
• Mother currently breast-feeding
• Had history of prolonged corrected QT interval (QTc) =500ms and/or known unstable or untreated cardiac disorder
• Had mild to severe renal impairment with Glomerular Filtration Rate <80 mililitre /min

Related Conditions & MeSH terms

• Mental Disorders
• Pharmacotherapy
• Psychotic Disorders
• Schizophrenia
• Schizophrenia and Related Disorders
• Stimulant Abuse
• Stimulant Dependence
• Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)

Intervention

Drug:
• Aripiprazole
for oral or depot preparation
• Paliperidone
for oral or depot

Other:
• Treatment as Usual
to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone

Locations

Country	Name	City	State
Hong Kong	Queen Mary Hospital	Hong Kong

Sponsors (3)

Lead Sponsor	Collaborator
The University of Hong Kong	North District Hospital, Queen Mary Hospital, Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative risk of psychosis relapse	The risk of relapse (rate and relative risk) for subjects receiving the active treatments with paliperidone and aripiprazole as compared to treatment as usual	36 months
Secondary	transition from diagnosis of substance induced psychosis to Schizophrenia as defined by DSM-5	The rate of transition from substance induced psychosis To schizophrenia in all 3 different arms	36 months
Secondary	change in stimulant use disorder as defined by DSM-5	The change is severity of the Stimulant Use Disorder in subjects in the 3 different arms by DSM-5 criteria	At 12th month and at 36th month
Secondary	Montreal Cognitive Assessment (MoCA)	Difference in cognitive outcome measured using MoCA in subjects randomized to the 3 arms	At 12th month and at 36th month
Secondary	Addiction Severity Index (ASL)-lite	Difference in functional outcome measured using ASL-lite in subjects randomized to the 3 treatment arms	At 12th and 36th months